To the editor:

The coronavirus disease 2019 (COVID-19) pandemic has caused unprecedented health care, economic, and psychosocial crises. We report a case series of 6 kidney and pancreas transplant recipients who presented in an unusually short time frame during the COVID-19 pandemic with transplant organ dysfunction and rejection ([Table 1](#tbl1){ref-type="table"} ). Mean time from the time of transplant to the current presentation was 7.3 ± 4 years. Of these 6 patients, 3 had severe allograft dysfunction requiring initiation of dialysis or insulin therapy. Two had a previous history of missing clinic visits. All patients presented with nonadherence during the "stay-at-home" social distancing orders. As the general socioeconomic status of our population is slightly above the general transplant population in the United States, these findings are concerning.Table 1Kidney and SPK transplant recipients admitted with acute rejection within 1 week of stay-at-home state orders during COVID-19 pandemicPtSexAge (yr)RaceTime since transplant (yr)Transplant typeInductionCause of ESRDMaintenance ISScr baseline (mg/dl)NonadherencePresentationScr at presentation (mg/dl)BiopsyTreatmentOutcomes1M43W5LUKTrATGPCKDT/M/P1.6YesNausea, vomiting30NDNoneDialysis2M37AA7LUKTIL-2 (−)HTNT/M/P1.3YesNausea, vomiting16TCMRPulse steroidsDialysis3M38W11SPKrATGDMT/M/P1YesNausea, vomiting1.5NDNoneFailed pancreas4F22W5DDrATGMCKDT/M/P0.9YesElevated UPC1ABMRPulse steroids i.v. Ig5F37W3LUKTrATGHTNT/M/P1.5YesElevated creatinine2.5MixedPulse steroids i.v. Ig6F59AA5DDrATGHTNT/L/P2YesElevated creatinine3ABMRIncrease baseline IS[^1]

Kidney transplant recipients infected with coronavirus have a significant risk of graft loss and death.[@bib1], [@bib2], [@bib3] However, the psychosocial impact of the COVID-19 pandemic on graft and patient outcomes in non-COVID kidney transplant recipients is unclear. The federal and local governments have enforced confinement orders to mitigate the spread of infection, but these restrictions have also limited health care access to "essential visits" only. Posttransplant management of solid organ transplant recipients is further compromised by loss of health insurance for many patients and cost reduction strategies at transplant centers.

Our case series suggests that rigorous, medical, and psychosocial risk stratification strategies are needed to avoid untoward outcomes in stable solid organ transplant recipients. Despite, or because of, the current financial crisis, the government and transplant centers need to consider further investment in life-long immunosuppression coverage,[@bib4] telehealth, mobile phlebotomy, noninvasive diagnostic tools, and person-power to keep their patients safe.

[^1]: AA, African American; ABMR, antibody-mediated rejection; COVID-19, coronavirus disease 2019; DD, deceased donor; DM, diabetes mellitus; ESRD, end-stage renal disease; F, female; HTN, hypertension; IL-2 (−), interleukin-2 blockade; IS, immunosuppression; LUKT, living unrelated kidney transplant; M, male; MCKD, medullary cystic kidney disease; ND, not done; PCKD, polycystic kidney disease; Pt, patient; rATG, rabbit antithymocyte globulin; Scr, serum creatinine; SPK, simultaneous pancreas-kidney transplantation; TCMR, T cell--mediated rejection; T/L/P, tacrolimus, leflunomide, prednisone; T/M/P, tacrolimus, mycophenolate, prednisone; UPC, urine protein-creatinine ratio; W, white.
